tbuckley/cabot-search huggingface dataset:
33830 Prognostic factors for early PASI 100 response in psoriasis patients treated with guselkumab: Results from the GUIDE study
Authors: Knut Schäkel, Kristian Reich, Khusru Asadullah, Andreas Pinter, Denis Jullien, Peter Weisenseel, Carle Paul, Mario Gomez, Sven Wegner, Yvonne Personke, Kilian Eyerich
Journal: Journal of the American Academy of Dermatology (2022)
33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
Authors: Maryanne M. Senna, Ohsang Kwon, Bianca Maria Piraccini, Rodney Sinclair, Susan Ball, Yuxin Ding, Yun-Fei Chen, Yves Dutronc, Brett King
Journal: Journal of the American Academy of Dermatology (2022)
34668 Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in psoriasis: Reductions in individual component scores and body regions of the Psoriasis Area and Severity Index in the phase 3 POETYK PSO-1 and PSO-2 trials
Authors: Jeffrey M. Sobell, Kilian Eyerich, Andrew Blauvelt
Journal: Journal of the American Academy of Dermatology (2022)
34513 Deucravacitinib efficacy in psoriatic arthritis by baseline DMARD use: Exploratory analysis from a phase 2 study
Authors: Atul Deodhar, Miroslawa Nowak, June Ye, Tom Lehman, Lan Wei, Subhashis Banerjee, Philip J. Mease
Journal: Journal of the American Academy of Dermatology (2022)
35205 Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and PSO-2 trials
Authors: Matthias Augustin, Bruce Strober, April W. Armstrong, Jennifer Beaumont, Tan P. Pham, Stacie Hudgens, Joe Zhuo, Brandon Becker, Subhashis Banerjee, Renata M. Kisa, Kim Papp
Journal: Journal of the American Academy of Dermatology (2022)
34794 Long-term safety and disease control of ruxolitinib cream among Black or African American patients with atopic dermatitis: Pooled results from 2 phase 3 studies
Authors: Lawrence F. Eichenfield, Linda F. Stein Gold, Zelma C. Chiesa Fuxench, May E. Venturanza, Haobo Ren, Kanwaljit K. Brar
Journal: Journal of the American Academy of Dermatology (2022)
33064 Correlation of fatigue severity and psoriasis severity, and the treatment effect of guselkumab: A detailed analysis of SF-36 vitality scores from the VOYAGE 2 study
Authors: Bruce Strober, Yi-hsuan Liu, Ya-Wen Yang, Megan Miller, Daphne Chan, Wolf-Henning Boehncke, Laura Savage, April Armstrong, Chenglong Han
Journal: Journal of the American Academy of Dermatology (2022)
33734 Patient education as the main target in skin cancer prevention: Knowledge, attitudes, and practices toward sun exposure and use of sun protection
Authors: David A. Castillo Molina, Jorge Andrés Rios-Duarte, Sara Muñoz-Ordoñez, Jesus Daniel Fierro-Lozada, Winnie Joanne Celorio-Murillo, Maria Fernanda Hernandez-Amaris, Maria J. Sanchez-Zapata, Criss Madeley Millan-Puerto
Journal: Journal of the American Academy of Dermatology (2022)
33184 The variable burden and impact of atopic dermatitis: A multi-method analysis of the More Than Skin Deep survey
Authors: Rawaan Elsawi, Aaron Drucker, Katie Dainty, Wei Wu, Lisa Butler, Korey Capozza, Sanaz Eftekhari, Kathryn T. Tullos, Wendy Smith Begolka
Journal: Journal of the American Academy of Dermatology (2022)
32937 Bimekizumab treatment response is maintained up to 3 years in patients with psoriatic arthritis: Responder analyses from BE ACTIVE, a phase 2b dose-ranging study, and its open-label extension
Authors: Joseph F. Merola, Akihiko Asahina, Christopher T. Ritchlin, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Jason Coarse, Jason Eells, Philip J. Mease
Journal: Journal of the American Academy of Dermatology (2022)
33884 Complete skin clearance for patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and health-related quality of life
Authors: Andrew Blauvelt, Mark Lebwohl, Alice Gottlieb, Matthias Augustin, Luis Puig, Paolo Eusebi, Christopher Cioffi, Balint Szilagyi, Susanne Wiegratz, Lars Iversen
Journal: Journal of the American Academy of Dermatology (2022)
34889 Comorbidity clusters and drug consumption patterns of patients with atopic dermatitis
Authors: Manuel Almenara-Blasco, Juan B. Perez-Gilaberte, Jonás Carmona-Pírez, Antonio Gimeno-Miguel, Beatriz Poblador-Plou, Alexandra Prados-Torres, Alba Navarro-Bielsa, Yolanda Gilaberte
Journal: Journal of the American Academy of Dermatology (2022)
34554 “Nothing really seemed to touch it that wasn’t a steroid”: An analysis of social media posts regarding the efficacy of topical corticosteroid use in atopic dermatitis
Authors: Jeffrey R. Rajkumar, Yasmin Gutierrez, Madison E. Jones, Sarah P. Pourali, Alison H. Kohn, April W. Armstrong
Journal: Journal of the American Academy of Dermatology (2022)
34414 Real-world treatment patterns of veterans with periocular basal cell carcinoma
Authors: Jamie Rhoads, Amber Jimenez, Kelli M. Rasmussen, Deborah Morreall, Vikas Patil, Christina Yong, Catherine Li, Janet Lee, Nindhana Paranthaman, Ahmad S. Halwani
Journal: Journal of the American Academy of Dermatology (2022)
33028 Direct and indirect treatment effect of guselkumab on anxiety and depression in patients with psoriasis by adjusting for Psoriasis Area and Severity Index (PASI) – A mediation analysis
Authors: April Armstrong, Peter Foley, Yan Liu, Ya-Wen Yang, Megan Miller, Rachel E. Teneralli, Anthony Bewley, Kenneth B. Gordon, Chenglong Han
Journal: Journal of the American Academy of Dermatology (2022)
32923 A multicenter, double-blind, randomized, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of spesolimab in patients with moderate-to-severe palmoplantar pustulosis
Authors: A. David Burden, Robert Bissonnette, Alexander A. Navarini, Masamoto Murakami, Akimichi Morita, Susan Mozzicato, Binqi Ye, Frank Baehner, Tadashi Terui
Journal: Journal of the American Academy of Dermatology (2022)
33468 Efficacy and safety of once-daily roflumilast cream 0.3% in patients with knee/elbow involvement: Pooled results from phase 3 trials (DERMIS-1 and DERMIS-2)
Authors: Laura K. Ferris, Zoe D. Draelos, Adelaide A. Hebert, Charles W. Lynde, David M. Pariser, Kim A. Papp, Paul S. Yamauchi, Amy Feng, Robert C. Higham, Patrick Burnett, David R. Berk
Journal: Journal of the American Academy of Dermatology (2022)
33467 Long-term safety and efficacy of roflumilast cream 0.3% in patients with chronic plaque psoriasis: Interim results from a 24-week, phase 3 open-label study
Authors: Kim A. Papp, David N. Adam, Melinda J. Gooderham, Lawrence J. Green, Mark Lebwohl, Angela Y. Moore, David M. Pariser, Amy Feng, Robert C. Higham, Patrick Burnett, David R. Berk
Journal: Journal of the American Academy of Dermatology (2022)
33532 Randomized split-face study to assess the efficacy and tolerability of M89PF as an adjunct to topical retinoids for antiaging benefits
Authors: Delphine Kerob, Priscial Correia, José Euzébio Gonçalves Junior, Erika Fernandes, Thais Pontes, Camila Valpaços, Diego Svoboda, Jerry Tan, Private Practice
Journal: Journal of the American Academy of Dermatology (2022)
33259 Improvements in anxiety and depression among patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2)
Authors: April Armstrong, Sandra McBride, Lynda Spelman, Pablo Fernández-Peñas, Phoebe Rich, George Martin, Nicola Tilt, Jose M. Lopez Pinto, Christina Popova, Scarlett Hellot
Journal: Journal of the American Academy of Dermatology (2022)
34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials
Authors: April W. Armstrong, Richard B. Warren, Howard Sofen, Lynda Spelman, Craig Leonardi, Subhashis Banerjee, Tao Wang, John Throup, Elizabeth Colston, Andrew Napoli, Alexa B. Kimball
Journal: Journal of the American Academy of Dermatology (2022)
33300 Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes repigmentation of stable lesions in patients with active nonsegmental vitiligo: Results from a phase 2b, randomized, placebo-controlled, dose-ranging study
Authors: Yuji Yamaguchi, Elena Peeva, Ronald Shore
Journal: Journal of the American Academy of Dermatology (2022)
34052 Facial pyoderma gangrenosum, a diagnostic challenge
Authors: Carmen Couselo-Rodríguez, Gonzalo Peón, Beatriz González-Sixto, Carlos Álvarez-Álvarez, Diego Soto-García, Sandra Martínez-Fernández, Raúl Gutiérrez-Mere, Ángeles Flórez
Journal: Journal of the American Academy of Dermatology (2022)
33233 Long-term efficacy (to 68 weeks) of baricitinib in adult patients with moderate to severe atopic dermatitis (AD) who were treatment responders or partial responders and originally included in the combination topical corticosteroids study BREEZE-AD7
Authors: Jonathan I. Silverberg, Eric L. Simpson, Jacob P. Thyssen
Journal: Journal of the American Academy of Dermatology (2022)
33553 Real-world treatment patterns and outcomes up to 1 year among children aged &lt;12 years with moderate-to-severe atopic dermatitis (AD) enrolled in the PEDIatric STudy in Atopic Dermatitis (PEDISTAD) observational study
Authors: Eulalia Baselga, Nikolay Murashkin, Myong Soon Sung, Lara Wine Lee, Chunyuan Liu, Lauren Bates, Annie Zhang
Journal: Journal of the American Academy of Dermatology (2022)
31854 Real-world experience of dupilumab treatment for atopic dermatitis
Authors: Jaime Martinez Mariscal, Raquel Cabana-Navia, Alicia Martinez-Fernandez, Adriana Martin-Fuentes, Ivan Checa-Recio, Patricia Gonzalez-Muñoz, Consuelo Sanchez-Herreros, Aranzazu Vergara, Maria-Antonia Pastor-Nieto, Esther Eusebio-Murillo
Journal: Journal of the American Academy of Dermatology (2022)
35158 Adaptations in the PURE registry in response to the COVID 19 pandemic: The impact of well-designed modifications in real-world data collection in a psoriasis registry
Authors: Charles Lynde, Kim Papp, Jennifer Beecker, Lorne Albrecht, Isabelle Delorme, Ignacio Dei-Cas, Antonio Vieira, Lenka Rihakova, Melinda Gooderham
Journal: Journal of the American Academy of Dermatology (2022)
33004 Dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite use of standard-of-care antihistamines: Results from a phase 3 trial (LIBERTY-CSU CUPID study A)
Authors: Marcus Maurer, Thomas B. Casale, Sarbjit S. Saini
Journal: Journal of the American Academy of Dermatology (2022)
33993 Oral difelikefalin improves itch and quality of life in subjects with itch-dominant atopic dermatitis: Subgroup analysis of a randomized, phase 2 study
Authors: Mark Lebwohl, Brian Kim, Joana Goncalves, Kristine Nograles, Catherine Munera, Gary Smith, Emma Guttman-Yassky
Journal: Journal of the American Academy of Dermatology (2022)
33181 C5a and C5aR is prominently associated with tunnels in severe hidradenitis suppurativa
Authors: Chris Li, Carolyn Dunlap, Bin Zhao, James Kilgour, None Karen Ebsworth, Peter Staehr, Israel Charo, Thomas Schall, Kavita Sarin, Kathleen Sullivan
Journal: Journal of the American Academy of Dermatology (2022)
33323 Dersimelagon, a melanocortin-1 receptor agonist, maintains efficacy regardless of seasons in subjects with erythropoietic protoporphyria: Results from a post hoc analysis of phase 2 clinical trial data
Authors: Kirstine Belongie, Fumihiro Takahashi, Sakiko Mukai, Mai Endou, Robert Desnick
Journal: Journal of the American Academy of Dermatology (2022)
33272 Fatigue in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from the CIMPACT phase 3 trial
Authors: Alice B. Gottlieb, Jennifer Soung, Andreas Pinter, Tsen-Fang Tsai, Jose Manuel Carrascosa, Julia-Tatjana Maul, Saakshi Khattri, Jose M. Lopez Pinto, Joseph F. Merola
Journal: Journal of the American Academy of Dermatology (2022)
32953 Efficacy responses across disease severity and treatment history subgroups of patients with moderate to severe plaque psoriasis treated with guselkumab: Pooled results from VOYAGE 1&amp;2 through 5 years
Authors: Kenneth B. Gordon, Joseph F. Merola, Peter Foley, Olivia Choi, Daphne Chan, Megan Miller, Yin You, Yaung-Kaung Shen, Ya-Wen Yang, Andrew Blauvelt
Journal: Journal of the American Academy of Dermatology (2022)
31686 Automatic detection of blue-white veil in melanoma based on multispectral dermoscopy
Authors: Bart Diricx, Jonas De Vylder, Sofie Mylle, Laudine Janssen, Sofie van Kelst, Evelien Verhaeghe, Lieve Brochez, Marjan Garmyn, Tom Kimpe
Journal: Journal of the American Academy of Dermatology (2022)
33354 Efficacy of apremilast in patients with mild to moderate psoriasis assessed by the physician global assessment and body surface area composite tool: Post hoc analysis from ADVANCE
Authors: Linda Stein Gold, Kim Papp, David Pariser, Howard Sofen, Mindy Chen, Sue Cheng, Hernan Picard, Yuri Klyachkin, Lawrence Green
Journal: Journal of the American Academy of Dermatology (2022)
33966 Integrated safety analysis of baricitinib in adults with severe alopecia areata from 2 randomized clinical trials
Authors: Brett King, Arash Mostaghimi, Yutaka Shimomura, Abraham Zlotogorski, Katrin Holzwarth, Maher Issa, Yves Dutronc, Sarah Stanley, Wen-Shuo Wu, Rodney Sinclair
Journal: Journal of the American Academy of Dermatology (2022)
34385 Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial
Authors: Lisa A. Beck, Mette Deleuran, H. Chih-ho Hong, David N. Adam, Iftikhar Hussain, Haixin Zhang, Arsalan Shabbir, Ainara Rodríguez Marco, Noah A. Levit
Journal: Journal of the American Academy of Dermatology (2022)
33556 Clinical efficacy of a new sunscreen containing Myrtus communis and Celastrol enriched plant cell culture extracts on reducing acne and limiting lesions’ recurrence post-sun exposure in acneic patients
Authors: Valerie Mengeaud, Priscilia Lapallud, Lilac Becdelièvre, Vriginie Ribet
Journal: Journal of the American Academy of Dermatology (2022)
33055 Guselkumab efficacy and safety through 5 years among psoriasis patients with and without metabolic syndrome at baseline: Results from VOYAGE 1 and VOYAGE 2
Authors: Joseph F. Merola, Diamant Thaçi, Olivia Choi, Daphne Chan, Ya-Wen Yang, Megan Miller, Yin You, Shu Li, Andrew Blauvelt, Luis Puig
Journal: Journal of the American Academy of Dermatology (2022)
33655 Noninvasive, in vivo, characterization of cutaneous metastases using a novel multimodal RCM-OCT imaging device: A case-series
Authors: Jilliana Monnier, Centre de Recherche en Can, Alexander S. Bang, Ucalene Harris, Jason Garfinkel, Gennady Rubinstein, Nicusor Iftimia, Melissa Pulitzer, Melissa Murray, Mario E. Lacouture, Manu Jain
Journal: Journal of the American Academy of Dermatology (2022)
34599 Achieving incrementally greater skin improvement thresholds with upadacitinib versus dupilumab in moderate-to-severe atopic dermatitis (AD): Heads Up study results
Authors: Jonathan I. Silverberg, Kilian Eyerich, Marjolein de Bruin-Weller, Brian M. Calimlim, Andrew M. Platt, Tianshuang Wu, Barry Ladizinski, Jacob P. Thyssen
Journal: Journal of the American Academy of Dermatology (2022)
33182 Safety of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata: Results from the ALLEGRO phase 2b/3, randomized, double-blind, placebo-controlled trial
Authors: Brett King, Jacek C. Szepietowski, Paul Farrant
Journal: Journal of the American Academy of Dermatology (2022)
32924 Sustained treatment effect of spesolimab over 12 weeks for generalized pustular psoriasis flares; results from the Effisayil 1 study
Authors: Boni Elewski, Jonathan Barker, Ulrich Mrowietz, Shinichi Imafuku, Na Hu, Manuel Quaresma, Christian Thoma
Journal: Journal of the American Academy of Dermatology (2022)
33152 Targeted combined endpoint improvement in patient and disease domains in atopic dermatitis (AD) among adults with moderate-to-severe AD treated with upadacitinib
Authors: Shawn G. Kwatra, Marjolein De Bruin-Weller, Peter Lio, Mette Deleuran, Sarah Ofori, Henrique D. Teixeira, Brian Calimlim, Yingyi Liu, Stephen Weidinger
Journal: Journal of the American Academy of Dermatology (2022)
34310 Bimekizumab early responses in patients with plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
Authors: Steven R. Feldman, Alice B. Gottlieb, Jennifer Soung, Matthias Augustin, Paolo Gisondi, Luke Peterson, Veerle Vanvoorden, Valerie Ciaravino, Natalie Nunez Gomez, Richard B. Warren
Journal: Journal of the American Academy of Dermatology (2022)
33255 Handwash formulations containing 12-hydroxystearic acid provide long-lasting protection against bacteria in vivo
Authors: Morris Waskar, Xuelan Gu, Meenakshi Swaminathan, Carol Vincent, Rimpa Ghosh, Chandraprabha Doraiswamy, Amitabha Majumdar
Journal: Journal of the American Academy of Dermatology (2022)
34631 Do patients with vitiligo and health care professionals treating them recognize the burden in living with the disease in the United States? Findings from the VALIANT study
Authors: Kristen Bibeau, John E. Harris, Iltefat H. Hamzavi, Anouk Lindley, Christine LaFiura, Khaled Ezzedine
Journal: Journal of the American Academy of Dermatology (2022)
35336 Do dermatologists realize a reliable clinical diagnosis of melanocytic nevi?
Authors: Marielva Castro-González, Nora Ximena Ugalde-Trejo, Estefanía Boland-Rodríguez, Abraham Benjamín Alfaro-Sánchez, Fermín R. Garza-González, Rebeca Rodríguez-Cabral
Journal: Journal of the American Academy of Dermatology (2022)
33356 A multinational chart review to examine gastrointestinal symptoms and their management in patients treated with apremilast for plaque psoriasis
Authors: Linda Stein Gold, Edward Tuttle, Wendy Y. Cheng, Rose Chang, Catherine Nguyen, Louise H. Yu, Anne Bouloc, Yuri Klyachkin, Tara Nazareth, Denis Jullien
Journal: Journal of the American Academy of Dermatology (2022)
33304 Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active nonsegmental vitiligo and either a lighter or darker Fitzpatrick skin type: Results from a phase 2b, randomized, dose-ranging study with an extension period
Authors: Elena Peeva, Yuji Yamaguchi, Brett King
Journal: Journal of the American Academy of Dermatology (2022)
33548 The patient burden of moderate-to-severe atopic dermatitis (AD) in Children aged &lt;12 years: Results from 732 patients in the PEDIatric STudy in Atopic Dermatitis (PEDISTAD) observational study
Authors: Amy S. Paller, Martti Antila, Danielle Marcoux
Journal: Journal of the American Academy of Dermatology (2022)
34312 Treatment with amlitelimab (KY1005, SAR445229): A novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis
Authors: Stephan Weidinger, Thomas Bieber, Michael Cork
Journal: Journal of the American Academy of Dermatology (2022)

Introduction: OX40Ligand-induced signaling promotes survival and functional activation of OX40+ Th2/Th17/Th22/Th1 cells, which are involved in atopic dermatitis (AD) pathogenesis and disease progression. In a phase 2a trial amlitelimab, a human nondepleting monoclonal anti-OX40Ligand antibody, was effective in treating patients with moderate to severe AD. Here we assessed its effects on interleukin (IL) 13, an important biomarker in AD. Methods and materials: Serum was collected during the Ph2a trial (NCT03754309, Kymab, a Sanofi Company-funded, double-blind, RCT). 89 moderate-to-severe AD patients were randomised 1:1:1 to intravenous amlitelimab low dose (LD, 200 mg loading/100 mg maintenance Q4W), high dose (HD, 500 mg/250 mg Q4W) or placebo (PBO). Disease severity measurement included EASI. Serum IL-13 levels were determined by single molecule immunoassay (Simoa). Results: Of 59 subjects who received amlitelimab, 44 were evaluable at W16. Amlitelimab was well tolerated with unremarkable safety profile. Mean % change in EASI from baseline (BL) at the primary end-point (Week16) was -80.1% for LD and -69.9% for HD vs -49.4% for PBO (P = .009 and .072 respectively). No BL difference in IL13 was found between groups. IL-13 levels correlated with disease severity at BL (r = 0.4784, P < .0001). A significant reduction in IL13 levels was observed at Week16 in Amlitelimab-treated patients (LD P < .0001; HD P = .0003) but not PBO (P = .1558). Conclusions: OX40Ligand blockade on APCs represents a promising novel approach in the treatment of AD. Amlitelimab monotherapy not only induced significant improvement in moderate-to-severe AD patients, but also significantly decreased serum IL13 levels, a Th2 cytokine associated with the underlying immunopathogenesis of AD.
33568 Evaluating the mildness of glycinate-based cleanser through in vitro methodologies and computational modeling
Authors: Siti Shahera Anwar, Melissa Tang, Abhinav Maheswaran Pragatheeswaran, Guo Liangfeng, Souvik Chakraborty, Kwek Jin Wang, Freda C.H. Lim
Journal: Journal of the American Academy of Dermatology (2022)
31069 Bimekizumab versus secukinumab in plaque psoriasis: Reduction in body surface area affected by psoriasis translates into benefits in patient-perceived itching, skin pain, and scaling and health-related quality of life in the BE RADIANT phase 3b trial
Authors: Matthias Augustin, Melinda Gooderham, Alice B. Gottlieb
Journal: Journal of the American Academy of Dermatology (2022)
34092 The distribution of nevi and melanoma in Caucasian and SOC individuals
Authors: Ryan Ladd, Jamison Harvey, Jake Besch-Stokes, Puneet Bhullar, Blake Boudreaux, Pranav Puri, Kevin Severson, Matthew Buras, Collin Costello, Helen Cumsky, Aaron Mangold
Journal: Journal of the American Academy of Dermatology (2022)
34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry
Authors: April W. Armstrong, Laura K. Ferris, Kristina Callis Duffin, Jud Janak, Adam Sima, Thomas Eckmann, Manish Patel, Huzefa Photowala, Vishvas Garg, Bruce Strober
Journal: Journal of the American Academy of Dermatology (2022)
33236 Impact of risankizumab on improving symptoms and health-related quality of life and reducing fatigue and pain among psoriatic arthritis patients with moderate-to-severe skin involvement: Evidence from 2 phase III trials
Authors: Kim Papp, Ahmed M. Soliman, Christian Kaufmann, Lisa Barcomb, Zailong Wang, Douglas White, Andrew Ostor, Lars Erik Kristensen
Journal: Journal of the American Academy of Dermatology (2022)
33322 Dupilumab improves patient-reported outcomes among adults with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study
Authors: Bruce Strober, Jingdong Chao, Chien-Chia Chuang, Min Yang, Brad Shumel, Jessie Wang, Gaelle Bego-Le-Bagousse, Debra Sierka, Zhixiao Wang, Dimittri Delevry
Journal: Journal of the American Academy of Dermatology (2022)
33781 Sustained and durable response up to 24 weeks after last dose observed in a phase 2a study (NCT03754309) of amlitelimab (KY1005, SAR445229) a novel nondepleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe atopic dermatitis (AD)
Authors: Stephan Weidinger, Thomas Bieber, Michael Cork, Adam Reich, Nuala Brennan, Sonia Quaratino, Rosamund Wilson, Ben Porter-Brown
Journal: Journal of the American Academy of Dermatology (2022)
34071 Combination of photodynamic therapy and oral antifungals for the treatment of onichomycosis
Authors: Alba Navarro-Bielsa, Tamara Garcia-Cazaña, Manuel Almenara-Blasco, Pilar Robres, Concepcion Lopez, M. Dolores Calvo-Priego, Yolanda Gilaberte
Journal: Journal of the American Academy of Dermatology (2022)
34714 Contextualization of skin cancer incidence rates in Costa Rica
Authors: Benjamin Gallo Marin, Andres Amaya, Daniel Marin Gamboa, Fabio Stefano Frech, David X. Zheng, Kathleen M. Mulligan, Rocío Oliva, Arturo Soto, Helena Kuhn
Journal: Journal of the American Academy of Dermatology (2022)